Henjum, Kristi http://orcid.org/0000-0001-9147-7282
Watne, Leiv Otto
Godang, Kristin
Halaas, Nathalie Bodd
Eldholm, Rannveig Saksholm
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Saltvedt, Ingvild http://orcid.org/0000-0002-7897-9808
Bollerslev, Jens
Knapskog, Anne Brita http://orcid.org/0000-0003-4867-551X
Article History
Received: 17 June 2021
Revised: 7 March 2022
Accepted: 14 March 2022
First Online: 9 April 2022
Competing interests
: ABK has been/is a principal investigator in Roche drug trials BN29553 and Novo Nordisk, NN6535-4730, and ABK and IS in Boehringer-Ingelheim drug trial 1346.0023. IS has been a consultant at the advisory board for Biogen. K.B. has worked as a consultant or at advisory boards or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.Z. has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen. KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors have no conflicts of interest to report.